Merck (NYSE:MRK) received positive CHMP opinions in Europe for two therapies across respiratory and oncology franchises. The committee backed expanded use of ENFLONSIA (clesrovimab) for RSV prevention...
Source LinkMerck (NYSE:MRK) received positive CHMP opinions in Europe for two therapies across respiratory and oncology franchises. The committee backed expanded use of ENFLONSIA (clesrovimab) for RSV prevention...
Source Link
Comments